Literature DB >> 8452120

Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up.

M Hakama1, M Lehtinen, P Knekt, A Aromaa, P Leinikki, A Miettinen, J Paavonen, R Peto, L Teppo.   

Abstract

Approximately 40,000 blood samples drawn in 1968-1972 by the Social Insurance Institution's mobile clinic in Finland have been stored. Linking cancer incidence data obtained from the Finnish Cancer Registry with this material yielded 32 cases of cervical cancer diagnosed after drawing of the blood sample. These 32 individuals and 64 matched controls were analyzed for serum antibodies indicative of past infection with Chlamydia trachomatis, Neisseria gonorrhoeae, cytomegalovirus, Epstein-Barr virus, and herpes simplex virus type 2. After adjustment for smoking and other sexually transmitted diseases, antibodies to C. trachomatis showed the strongest association with cervical cancer (odds ratio = 5.0 (95% confidence interval 1.6-15.7)), but the numbers were too small for drawing conclusions as to the sexually transmitted diseases with which cervical cancer is most specifically associated.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8452120     DOI： 10.1093/oxfordjournals.aje.a116656

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN： 0002-9262            Impact factor:   4.897


  10 in total

Review 1.  Recent trends in the epidemiology of sexually transmitted infections in the European Union.

Authors:  K A Fenton; C M Lowndes
Journal:  Sex Transm Infect       Date:  2004-08       Impact factor: 3.519

2.  Prevalence of Chlamydia trachomatis infections among women from different settings in China: implications for STD surveillance.

Authors:  X-S Chen; Y-P Yin; D Mabey; R W Peeling; H Zhou; W-H Jiang; W-H Wei; G Yong; M-Q Shi; Q Chen; X Gao
Journal:  Sex Transm Infect       Date:  2006-08       Impact factor: 3.519

Review 3.  Is screening for Chlamydia trachomatis infection cost effective?

Authors:  J Paavonen
Journal:  Genitourin Med       Date:  1997-04

4.  Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study.

Authors:  M Lehtinen; J Dillner; P Knekt; T Luostarinen; A Aromaa; R Kirnbauer; P Koskela; J Paavonen; R Peto; J T Schiller; M Hakama
Journal:  BMJ       Date:  1996-03-02

5.  Specific chlamydial inclusion membrane proteins associate with active Src family kinases in microdomains that interact with the host microtubule network.

Authors:  Jeffrey Mital; Natalie J Miller; Elizabeth R Fischer; Ted Hackstadt
Journal:  Cell Microbiol       Date:  2010-03-19       Impact factor: 3.715

6.  Herpes simplex virus type 2 infection and cervical cancer: a prospective study of 12 years of follow-up in Finland.

Authors:  M Lehtinen; M Hakama; R K Aaran; A Aromaa; P Knekt; P Leinikki; J Maatela; R Peto; L Teppo
Journal:  Cancer Causes Control       Date:  1992-07       Impact factor: 2.506

Review 7.  Cervical cancer: is herpes simplex virus type II a cofactor?

Authors:  C Jones
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

8.  Clinic-based evaluation of Clearview Chlamydia MF for detection of Chlamydia trachomatis in vaginal and cervical specimens from women at high risk in China.

Authors:  Y-P Yin; R W Peeling; X-S Chen; K-L Gong; H Zhou; W-M Gu; H-P Zheng; Z-S Wang; G Yong; W-L Cao; M-Q Shi; W-H Wei; X-Q Dai; X Gao; Q Chen; D Mabey
Journal:  Sex Transm Infect       Date:  2006-11-22       Impact factor: 3.519

9.  No association of anti-Chlamydia trachomatis antibodies and severity of cervical neoplasia.

Authors:  N Reesink-Peters; J M Ossewaarde; A G Van Der Zee; W G Quint; M P Burger; A H Adriaanse
Journal:  Sex Transm Infect       Date:  2001-04       Impact factor: 3.519

10.  Prevalence and determinants of Chlamydia trachomatis infections in women from Bogota, Colombia.

Authors:  M Molano; E Weiderpass; H Posso; S A Morré; M Ronderos; S Franceschi; A Arslan; C J L M Meijer; N Muñoz; A J C van den Brule
Journal:  Sex Transm Infect       Date:  2003-12       Impact factor: 3.519
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.